A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Bortezomib

Criteria

Inclusion Criteria:

• Good performance status

• Histologic evidence of multiple myeloma

• Have had at least three prior treatment regimens for multiple myeloma that included both bortezomib and lenalidomide

• No prior treatment with a heat shock 90 inhibitor or an investigational proteasome inhibitor

• No known infections of HAV, HBV, HCV, or HIV

• No chemotherapy, radiation therapy, or immune therapy for three weeks prior to enrollment.